News
AKBA
0.6999
+5.98%
0.0395
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 2d ago
Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
Benzinga · 2d ago
Weekly Report: what happened at AKBA last week (1019-1023)?
Weekly Report · 2d ago
Akebia Therapeutics, Inc. Receives Nasdaq Minimum Bid Price Deficiency Notice
NASDAQ · 4d ago
Akebia Therapeutics Faces Nasdaq Listing Compliance Challenge
TipRanks · 4d ago
Weekly Report: what happened at AKBA last week (1012-1016)?
Weekly Report · 10/19 09:41
Akebia Therapeutics Announces CCO Resignation and Advisory Role
TipRanks · 10/14 12:19
Weekly Report: what happened at AKBA last week (1005-1009)?
Weekly Report · 10/12 09:44
Weekly Report: what happened at AKBA last week (0928-1002)?
Weekly Report · 10/05 09:43
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 10/01 15:05
Weekly Report: what happened at AKBA last week (0921-0925)?
Weekly Report · 09/28 09:41
Scynexis appoints Burke to Board of Directors
TipRanks · 09/22 12:16
Weekly Report: what happened at AKBA last week (0914-0918)?
Weekly Report · 09/21 09:41
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Hyperfine (HYPR)
TipRanks · 09/15 10:30
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
Benzinga · 09/15 09:49
Akebia doses first patient in ebribafusp trial
TipRanks · 09/14 12:15
Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
Benzinga · 09/14 12:04
Weekly Report: what happened at AKBA last week (0907-0911)?
Weekly Report · 09/14 09:44
WestPark Capital Initiates Coverage of Akebia Therapeutics with Buy Rating
NASDAQ · 09/08 23:11
Akebia Therapeutics Price Target Announced at $4.50/Share by WestPark Capital
Dow Jones · 09/08 15:48
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.